EU widens Bavarian Nordic mpox shot use
2026-08-08
"Children have carried a disproportionate burden" now doubles as both warning and policy trigger, as the European Medicines Agency has expanded Bavarian Nordic’s smallpox and mpox vaccine approval to include paediatric use across the bloc.
This move is less a surprise than a late alignment with outbreak reality, regulators responding to clusters where infection rates and household exposure patterns pushed minors into the front line of mpox transmission chains. The vaccine, based on a non‑replicating modified vaccinia Ankara platform and already cleared for adults, can now be used in children under a harmonised product label, after immunogenicity and safety data from observational studies and post‑marketing pharmacovigilance suggested comparable antibody responses.
What changes now is bargaining power in public health planning, as authorities gain legal room to add children to stockpiling models and ring‑vaccination protocols without resorting to ad hoc exemptions or off‑label workarounds. Outgoing Bavarian Nordic chief executive Paul Chaplin framed the decision as a direct answer to paediatric case patterns seen in recent outbreaks, giving the company both reputational capital and a stronger foothold in future procurement rounds, even as debates continue over dose‑splitting strategies and equitable access outside high‑income regions.
Loading...
